DPX-COVID-19

DPX-COVID-19

A Vaccine Designed to Generate a Targeted and Sustained Protection Against COVID-19

Based on our previous clinical data in oncology and infectious diseases, DPX-COVID-19 has the potential to improve the duration of the immune response and protect older adults and more vulnerable individuals

Click on the picture to watch the report broadcast on CTV News on April 29, 2020

* Peptide epitopes are information molecules that can very precisely direct immune responses toward specific areas exposed on the surface of the virus.

A Vaccine Designed to Protect the Most Vulnerable

When the COVID-19 pandemic began, researchers at IMV quickly transitioned from working in cancer research to focusing on a COVID-19 vaccine.
The biotech firm now has received positive feedback from Health Canada to include older adults of 56 years and above in its clinical studies.

Click on the picture to watch the interview on CTV News on July 16, 2020

DPX-COVID-19 At-a-Glance

A Multi-Target Approach Based On Our DPX Platform

DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection and reduce potential for immune escape, even in case of a virus mutation.

Potential for Fast and Large-scale Manufacturing

Fully synthetic, DPX-COVID-19 has the potential for fast and large-scale manufacturing to supply a significant number of doses rapidly compared to more conventional vaccines.
Our vaccine candidate is stable and transportable at room temperature and 2°-8°C for at least 3 months

A large Phase 1/2 study to expedite later-stage development

Allied with Renowned Experts

The Research Centre on Infectious Diseases at the University Laval in Quebec City

  • Some of our pre-clinical studies in animal models are run in collaboration with Dr. Gary Kobinger.
View CRI

The Canadian Immunization Research Network (CIRN)

  • CIRN will perform Phase 1 Clinical studies.
  • Dr. Joanne Langley and Dr. Scott Halperin from the Canadian Center for Vaccinology (CCfV) in Halifax, NS.
  • McGill Health Center (MUHC) in Montreal, QC.
View CIRN

Frequently Asked Questions

How was IMV's vaccine designed?

The Company has used sequences of the virus and immunoinformatics to predict and identify several hundred epitopes, of which 23 were selected for their biological relevance to the virus and potential to generate neutralizing antibodies against SARS-CoV-2.

Peptide epitopes are information molecules that can direct our immune system against targeted areas exposed on the surface of a virus. There are typically thousands of epitopes on viruses, but few have the potential to effectively neutralize and prevent the infection. IMV’s researchers utilized predicted epitopes from the literature and selected peptide epitopes representing the most promising immunological “Achilles heel” of the coronavirus.

IMV has formulated selected peptide epitopes with its DPX platform which has a unique mechanism of action and activates a targeted and sustained immune response. The benefit of this targeted and prolonged delivery is a potential increase in safety and efficacy by exclusively focusing the attack of the immune system onto the spike proteins of the virus.

IMV’s selected vaccine candidate is designed to target non-overlapping neutralizing epitopes with the potential to act synergistically on 3 different key mechanisms of infection of the virus (see the picture above).

DPX-COVID-19 utilizes a multi-target approach, to optimize immune response against virus’ weaknesses, enhance efficacy at preventing infection, and reduce the potential for immune escape, even in case of a virus mutation.

Is the efficacy of DPX-COVID-19 impacted by the recent mutations of the virus?

DPX-COVID-19 is a formulation of the DPX delivery platform with four complementary peptide antigens that were selected for their high immunogenicity and potential ability to bind non-overlapping areas on the virus spike and impact its infective function.

None of the recent mutations reported in UK or in Denmark (mink) are in the areas of the four selected peptides in DPX-COVID-19. By targeting areas less prone to mutations DPX-COVID-19 has potential to offer protection against a broader range of circulating variants.

What is the difference between IMV’s DPX-based vaccine and traditional vaccines?

The DPX platform is formulated with small peptides that are present at the surface of the virus. DPX-COVID-19 has the potential to generate a targeted and sustained immune response against these peptides and eliminate the virus with expected limited side effects. It has the potential to be used widely, including aged adults and people with weakened immune systems and long-term health problems.

Conventional vaccines typically use the whole virus (live-attenuated or inactivated) to trigger an immune response. Since viruses have a complex structure, it is difficult to know which elements generate the immune response. Conventional vaccines have some limitations and may induce unwanted immune-related side effects, especially in people with weakened immune systems, long-term health problems, or people who’ve had an organ transplantii.

The benefit of a targeted and prolonged approach is a potential increase in safety and efficacy by exclusively focusing the attack of the immune system onto the weaknesses of the virus.

The Company is currently working on a manufacturing method that will allow handling in a lyophilized formulation that can be stored at 2°- 8°C and room temperature for at least 3 months, allowing for long term stability and cold chain management with existing infrastructure. 

Why is it easy and fast to produce DPX-COVID-19?

All DPX-based therapies are fully synthetic, which means that there are no biologic components in the formulation and does not require any biologic manufacturing processes.

The Company is currently working on a manufacturing method that will allow handling in a lyophilized formulation that can be stored at 2°- 8°C and room temperature for at least 3 months, allowing for long term stability and cold chain management with existing infrastructure. 

When did IMV announce the development of a vaccine against COVID-19?

IMV made an official announcement on March 18 in a press release when the top peptide epitopes were successfully identified and selected for development and has provided updates in a second press release issued on March 30. On May 21, 2020, the Company has announced the selection of its vaccine candidate in a press release.